NeuroSense Therapeutics Ltd. (NRSN)
|Net Income (ttm)||-13.51M|
|Day's Range||1.57 - 2.09|
|52-Week Range||1.08 - 4.47|
|Earnings Date||Jun 1, 2023|
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and ... [Read more]
Financial PerformanceFinancial Statements
NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
CAMBRIDGE, Mass. , June 1, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
96% of participants who completed the trial opted to receive treatment with PrimeC in a 12-month open label extension Topline results expected Q4 2023 CAMBRIDGE, Mass. , May 15, 2023 /PRNewswire/ -- N...
NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study
Statistically significant decreased levels of novel biomarker AGO2 (p= 0.002) observed in newly diagnosed people living with Parkinson's disease (PD) compared to healthy individuals NeuroSense's combi...
NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
CAMBRIDGE, Mass., April 17, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an up...
NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
In vitro studies to test the effects of PrimeC on key pathways involved in ALS including TDP-43 accumulation, autophagy defects, mitochondrial dysfunction, and oxidative stress Preliminary results fro...
NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
Biomarkers show potential efficacy PrimeC is currently being evaluated for the treatment of ALS in a Phase 2b study with topline results expected in H2 2023 Phase 2 double-blind proof-of-concept AD st...
NeuroSense Announces Year End 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass., March 22, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that...
NeuroSense Therapeutics to Participate in BIO-Europe Spring
CAMBRIDGE, Mass. , March 16, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NEUROSENSE THERAPEUTICS LTD. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023
CAMBRIDGE, Mass. , March 14, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts
View video here: LINK CAMBRIDGE, Mass. , Feb. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
QuantalX's direct electrophysiology imaging technology (Delphi-MD) expected to provide multiple clinically objective and accurate measurements in NeuroSense's Phase 2 double-blind proof-of-concept cli...
NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
PARADIGM protocol is approved in four countries: Israel, Italy, Canada, and Germany Topline results expected in H2 2023 CAMBRIDGE, Mass. , Feb. 8, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study
Receives regulatory approval from Health Canada to commence enrollment PARADIGM topline read-out expected H2 2023 CAMBRIDGE, Mass. , Feb. 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study
Elevated levels of novel biomarker TDP-43 in Alzheimer's disease (AD) show the therapeutic potential of NeuroSense's combination platform Phase 2 double-blind proof-of-concept clinical study expected ...
NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass. , Dec. 1, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS
CAMBRIDGE, Mass. , Nov. 16, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study
NeuroSense Therapeutics receives FDA clearance to commence patient enrollment in the U.S. with PrimeC, a novel combination therapy Follows a successful U.S. pharmacokinetic (PK) study which confirmed ...
NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences
CAMBRIDGE, Mass. , Oct. 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany
CAMBRIDGE, Mass , Oct. 21, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its p...
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video
View the Nasdaq Opening Bell Ringing & CEO Message Here: LINK CAMBRIDGE, Mass. , Oct. 18, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on October 13, 2022 in New York City
Investors and analysts interested in participating in the Summit via webinar may register here: LINK CAMBRIDGE, Mass. , Oct. 12, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference
Company's lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023 CAMBRIDGE, Mass. , Sept. 29, 2022 /PRNewswire/ -- NeuroSense Therapeutics...
NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US
Pharmacokineticic (PK) profile of PrimeC supports the formulation's extended release properties, as the active components are released simultaneously CAMBRIDGE, Mass. , Sept. 28, 2022 /PRNewswire/ -- ...
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
Biomarker data to be presented provide indication of PrimeC's efficacy in ALS Phase IIb PARADIGM ALS trial's primary endpoints include biomarkers and ALS-related hallmarks Topline results expected H1 ...
NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial
PrimeC is safe and tolerable at over 4x the maximal clinical dose Data support current Phase IIb PARADIGM study design, new PrimeC formulation, and potential favorable clinical trial outcome CAMBRIDGE...